TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27892641

Group type: EXPERIMENTAL
Intervention: Text + Picture stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Text-only stimuli
Number of subjects: 0
Study: 25248303

Group type: EXPERIMENTAL
Intervention: Affective expectation manipulation
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Affective expectation manipulation with elaboration
Number of subjects: 148

Group type: COMPARATOR
Intervention: No-expectation participants
Number of subjects: 148

Group type: COMPARATOR
Intervention: No-elaboration participants
Number of subjects: 148
Study: 23597479

Group type: EXPERIMENTAL
Intervention: Point-of-care assessment using high-sensitivity cardiac troponin assays
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Simultaneous measurement of H-FABP and cTnT or cTnI
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin measured on admission
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: 10-hour troponin measurement
Number of subjects: 850

Group type: COMPARATOR
Intervention: Admission myoglobin
Number of subjects: 850

Group type: COMPARATOR
Intervention: CK-MB measurement on admission
Number of subjects: 850

Group type: COMPARATOR
Intervention: Copeptin measurement on admission
Number of subjects: 850

Group type: COMPARATOR
Intervention: NTproBNP measurement on admission
Number of subjects: 850
Study: 21798501

Group type: EXPERIMENTAL
Intervention: Warfarin treatment
Number of subjects: 9113
Study: 19459015

Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery programs
Number of subjects: 4

Group type: COMPARATOR
Intervention: Traditional postoperative care
Number of subjects: 4
Study: 16809994

Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg intravenous bolus)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone (2-4 mg given over 30 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone (2-3 mg bolus followed by continuous infusion of 4 mg/h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone (5 mg or greater)
Number of subjects: 0
Study: 12832434

Group type: EXPERIMENTAL
Intervention: Strength training (BRTr)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (BRCon)
Number of subjects: 12
Study: 10836723

Group type: EXPERIMENTAL
Intervention: Short-term exercise (42-km marathon)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term exercise (15-km race)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supervised exercise on a treadmill for CAD patients (30 min at 80% of maximal heart rate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12-week cardiac rehabilitation program for CAD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basal urinary excretion of cGMP in highly trained runners, sedentary subjects, and CAD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basal levels of cGMP in CAD patients after 12-week cardiac rehabilitation
Number of subjects: 0
Study: 9180622

Group type: EXPERIMENTAL
Intervention: Active biofeedback treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo biofeedback treatment
Number of subjects: 56
Study: 8256752

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 0
Study: 2579879

Group type: EXPERIMENTAL
Intervention: Oral propafenone 300 mg t.i.d.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intravenous propafenone 1.5 mg/kg in three minutes.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 30690595

Group type: EXPERIMENTAL
Intervention: Lung lavage with diluted porcine surfactant (30 ml/kg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Bolus surfactant (100 mg/kg)
Number of subjects: 33
Study: 29894840

Group type: EXPERIMENTAL
Intervention: Selective SWS suppression during night sleep
Number of subjects: 12

Group type: COMPARATOR
Intervention: Regular night sleep (control)
Number of subjects: 12
Study: 27045451

Group type: EXPERIMENTAL
Intervention: Mental visual imagery (MVI) programme
Number of subjects: 17

Group type: COMPARATOR
Intervention: Verbal control programme
Number of subjects: 17
Study: 24755958

Group type: EXPERIMENTAL
Intervention: Sunitinib (37.5 mg/d) in combination with docetaxel (75 mg/m2)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sunitinib/docetaxel
Number of subjects: 27
Study: 23234575

Group type: EXPERIMENTAL
Intervention: Walking and Behavioural intervention (WB)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Walking intervention (W)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Self‐directed control (C)
Number of subjects: 222
Study: 19734030

Group type: EXPERIMENTAL
Intervention: Moderate emphysema (ES910) with apical distribution
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Severe emphysema (ES950) with apical distribution
Number of subjects: 875
Study: 18276127

Group type: EXPERIMENTAL
Intervention: DHA supplementation (algal DHA-rich oil)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sunflower seed oil (control)
Number of subjects: 17
Study: 15558238

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 361

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study: 12063368

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization
Number of subjects: 453
Study: 10474062

Group type: EXPERIMENTAL
Intervention: 10 mg of DUP 996
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 20 mg of DUP 996
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 30 mg of DUP 996
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 8607407

Group type: EXPERIMENTAL
Intervention: Caffeine (3.3 mg/kg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 1708214

Group type: EXPERIMENTAL
Intervention: Pentamorphone 0.24 micrograms/kg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pentamorphone 0.16 micrograms/kg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pentamorphone 0.08 micrograms/kg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 6136691

Group type: EXPERIMENTAL
Intervention: Isotonic saline irrigation via a special dressing
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional saline dressings
Number of subjects: 12
Study: 30667189

Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fissure sealant
Number of subjects: 0
Study: 28325960

Group type: EXPERIMENTAL
Intervention: Paracetamol-Codeine (analgesic group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (placebo group)
Number of subjects: 32
Study: 26747845

Group type: EXPERIMENTAL
Intervention: web‐based TF‐CBT training + consultation (W)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: W + 2 day live TF‐CBT workshop + twice monthly phone consultation (W + L)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: TF‐CBT (across conditions)
Number of subjects: 129
Study: 24368034

Group type: EXPERIMENTAL
Intervention: Amplitude-modulated stimulus (AM-SSVEP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-frequency SSVEP
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-frequency SSVEP
Number of subjects: 0
Study: 22971521

Group type: EXPERIMENTAL
Intervention: 6 repeat intradermal injections of grass pollen extract (7 ng of Phl p 5 per injection) at 2-week intervals
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2 intradermal injections separated by 10 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: A single intradermal injection at 10 weeks
Number of subjects: 30
Study: 19397752

Group type: EXPERIMENTAL
Intervention: i.v. dexamethasone (0.5 mg/kg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study: 17599563

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 72
Study: 15179544

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day, orally)
Number of subjects: 8
Study: 11251702

Group type: EXPERIMENTAL
Intervention: 1 g intravenous magnesium sulfate
Number of subjects: 30

Group type: COMPARATOR
Intervention: 10 mL of 0.9% saline (placebo)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1 g intravenous magnesium sulfate (after placebo)
Number of subjects: 30
Study: 9647567

Group type: EXPERIMENTAL
Intervention: Co-culture with human fibroblasts
Number of subjects: 148

Group type: COMPARATOR
Intervention: Conventional culture
Number of subjects: 148
Study: 8005254

Group type: EXPERIMENTAL
Intervention: 50 mg codeine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 50 mg naltrexone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 2557184

Group type: EXPERIMENTAL
Intervention: Prevent dentifrice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colgate TCF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crest Tartar Control Formula
Number of subjects: 0
Study: 30453682

Group type: EXPERIMENTAL
Intervention: High Glycemic Index meal (HGI)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low Glycemic Index meal (LGI)
Number of subjects: 10
Study: 28655036

Group type: EXPERIMENTAL
Intervention: Simultaneous BiCIs (2 cochlear implants during 1 surgical procedure)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sequential BiCIs (2 cochlear implants with an interval of 2 years between implants)
Number of subjects: 40
Study: 25468586

Group type: COMPARATOR
Intervention: No head elevation
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Sniffing position (6.0 cm head elevation)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Elevated sniffing position (10.0 cm head elevation)
Number of subjects: 167
Study: 23989945

Group type: EXPERIMENTAL
Intervention: Home treatment
Number of subjects: 97

Group type: COMPARATOR
Intervention: Combined community locations (home and GP)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Hospital treatment
Number of subjects: 97

Group type: COMPARATOR
Intervention: Community treatment (home and GP)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: All treatment locations
Number of subjects: 97

Group type: COMPARATOR
Intervention: GP surgeries
Number of subjects: 97
Study: 21928195

Group type: EXPERIMENTAL
Intervention: Thrombin bolus injection
Number of subjects: 73

Group type: COMPARATOR
Intervention: Thrombin slow injection
Number of subjects: 73
Study: 17940111

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone patches
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16513420

Group type: EXPERIMENTAL
Intervention: ICD+CRT
Number of subjects: 31

Group type: COMPARATOR
Intervention: ICD alone
Number of subjects: 31
Study: 15081434

Group type: EXPERIMENTAL
Intervention: DCA plus stenting
Number of subjects: 753

Group type: COMPARATOR
Intervention: Stenting alone
Number of subjects: 753
Study: 11544429

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 26
Study: 9244018

Group type: EXPERIMENTAL
Intervention: Oesophageal Doppler monitor
Number of subjects: 16

Group type: COMPARATOR
Intervention: Continuous cardiac output monitor
Number of subjects: 16
Study: 8015566

Group type: EXPERIMENTAL
Intervention: Bifonazole 1% cream
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (vehicle)
Number of subjects: 100
Study: 3552845

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg x 2)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Cimetidine (400 mg x 2)
Number of subjects: 444
Study: 29809161

Group type: EXPERIMENTAL
Intervention: Becaplermin gel plus good wound care (BGWC)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo gel plus good wound care (control)
Number of subjects: 62
Study: 27296439

Group type: EXPERIMENTAL
Intervention: Fines for nonattendance (intervention arm includes a letter explaining fines for nonattendance)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual practice (control arm with no letter attachment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fines for nonattendance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 0
Study: 24423298

Group type: EXPERIMENTAL
Intervention: 10 mg of pegvisomant
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 23539702

Group type: EXPERIMENTAL
Intervention: Active intense pulsed light (IPL) treatment
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo IPL treatment
Number of subjects: 47
Study: 19874632

Group type: EXPERIMENTAL
Intervention: Liquid yogurt
Number of subjects: 18

Group type: COMPARATOR
Intervention: Chocolate bars
Number of subjects: 18
Study: 17764767

Group type: EXPERIMENTAL
Intervention: High Dose (HD) group (10^8 cells)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low Dose (LD) group (10^7 cells)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (C) group (no cell transplantation)
Number of subjects: 60
Study: 16888455

Group type: EXPERIMENTAL
Intervention: Antioxidant (AO) supplementation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 16
Study: 12552359

Group type: EXPERIMENTAL
Intervention: Modafinil 300 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: d-Amphetamine 20 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 10986991

Group type: EXPERIMENTAL
Intervention: Skin traction
Number of subjects: 120

Group type: COMPARATOR
Intervention: No special treatment
Number of subjects: 120
Study: 8971315

Group type: EXPERIMENTAL
Intervention: Transcutaneous stimulation of P6 and Li4
Number of subjects: 84

Group type: COMPARATOR
Intervention: No stimulation (control group)
Number of subjects: 84
Study: 1432432

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low dopamine (2 micrograms/kg per minute)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High dopamine (5 micrograms/kg per minute)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All groups (Placebo, Low dopamine, High dopamine)
Number of subjects: 36
Study: 3917900

Group type: EXPERIMENTAL
Intervention: 10 cm2 nitroglycerin plaster
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 cm2 nitroglycerin plaster
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (15 cm2 plaster)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5 cm2 nitroglycerin plaster
Number of subjects: 12
Study: 31258016

Group type: EXPERIMENTAL
Intervention: Parent mental health screening
Number of subjects: 0
Study: 30053413

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) for 12 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (healthy middle-aged and healthy elderly)
Number of subjects: 12
Study: 27296693

Group type: EXPERIMENTAL
Intervention: rTSST-1v (100 ng to 30 μg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Al(OH)3 (200 μg, 600 μg, or 1 mg)
Number of subjects: 46
Study: 26060452

Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mild intensity aerobic exercise training
Number of subjects: 50
Study: 23447898

Group type: EXPERIMENTAL
Intervention: CXL group (collagen cross-linking)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No CXL group (control)
Number of subjects: 34
Study: 20395895

Group type: COMPARATOR
Intervention: 0 mL saline
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 5 mL saline
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 10 mL saline
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 15 mL saline
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 20 mL saline
Number of subjects: 75
Study: 18304239

Group type: COMPARATOR
Intervention: Fluoridated toothpaste (1100 ppm) - Group A (positive control)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Non-fluoridated toothpaste - Group B (negative control)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Tooth Mousse containing CPP-ACP as a toothpaste - Group C
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Tooth Mousse containing CPP-ACP as a topical coating - Group D
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Tooth Mousse containing CPP-ACP as a topical coating after fluoridated toothpaste - Group E
Number of subjects: 5
Study: 16253978

Group type: EXPERIMENTAL
Intervention: OC-scheduled GnRH antagonist (ganirelix)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 332

Group type: COMPARATOR
Intervention: Non-scheduled GnRH antagonist
Number of subjects: 332
Study: 12108857

Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg, twice daily via Turbuhaler
Number of subjects: 912

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 912
Study: 10540367

Group type: EXPERIMENTAL
Intervention: Double filtration plasmapheresis (DFPP)
Number of subjects: 16
Study: 7484629

Group type: EXPERIMENTAL
Intervention: MR imaging quantification method for estimation of total volumes of subcortical lesions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MR imaging quantification method for estimation of ventricular CSF volumes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subcortical lesion volume estimation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ventricular CSF volume estimation
Number of subjects: 12
Study: 1967210

Group type: EXPERIMENTAL
Intervention: Weight loss plus atenolol
Number of subjects: 692

Group type: COMPARATOR
Intervention: Usual diet plus chlorthalidone
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Active drug plus weight loss groups
Number of subjects: 692
Study: 366719

Group type: EXPERIMENTAL
Intervention: Aspirin (5 grain ASA capsules)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (lactose placebo)
Number of subjects: 30
Study: 30773861

Group type: EXPERIMENTAL
Intervention: Acupuncture of EX-B2
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 40
Study: 28321638

Group type: EXPERIMENTAL
Intervention: Graduated compression stockings (pressures of 26.4 ± 5.3, 17.5 ± 4.4, and 6.1 ± 2.0 mmHg at the ankle, calf, and thigh, respectively)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Loose‐fitting stockings (Control)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Graduated compression stockings
Number of subjects: 9

Group type: COMPARATOR
Intervention: Graduated compression stockings and Control
Number of subjects: 9
Study: 25823275

Group type: EXPERIMENTAL
Intervention: Umifenovir 200 mg four times daily for 5 days
Number of subjects: 293

Group type: COMPARATOR
Intervention: Placebo four times daily for 5 days
Number of subjects: 293
Study: 24055306

Group type: EXPERIMENTAL
Intervention: Fluzone(®) Intradermal vaccine
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Fluzone(®) Intramuscular vaccine
Number of subjects: 1250
Study: 21865396

Group type: EXPERIMENTAL
Intervention: H5N1 VLP vaccine at 15, 45, or 90 μg HA/dose
Number of subjects: 0
Study: 19509109

Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 67

Group type: COMPARATOR
Intervention: Oral hypoglycemic agents (OHA)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 67
Study: 17991662

Group type: EXPERIMENTAL
Intervention: Plasma n-3 PUFA proportions
Number of subjects: 807
Study: 10620209

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 212

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 212
Study: 8859184

Group type: EXPERIMENTAL
Intervention: Patient reminder intervention
Number of subjects: 2368

Group type: EXPERIMENTAL
Intervention: Physician reminder intervention
Number of subjects: 2368
Study: 1644089

Group type: EXPERIMENTAL
Intervention: Captopril (up to 150 mg/day for 6 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6084121

Group type: EXPERIMENTAL
Intervention: Guanabenz 16 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Guanabenz (2 to 32 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Guanabenz 16 mg (sublingual and oral)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31555926

Group type: EXPERIMENTAL
Intervention: 10-day normobaric hypoxic confinement (FiO2=0.14) with daily 90-min normoxic controlled hyperthermia (target rectal temperature: 38.5 °C)
Number of subjects: 8
Study: 29969301

Group type: EXPERIMENTAL
Intervention: L-ornithine (400 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 27125345

Group type: EXPERIMENTAL
Intervention: RIX4414 vaccine
Number of subjects: 6466

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6466
Study: 25078901

Group type: EXPERIMENTAL
Intervention: Closed-loop control
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 24
Study: 23149929

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Mirabegron 100 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Mirabegron 200 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 20336066

Group type: EXPERIMENTAL
Intervention: Aleglitazar (20, 50, 100, 300, 600, or 900 microg)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Aleglitazar (doses >300 microg)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 18606930

Group type: EXPERIMENTAL
Intervention: Birth attendant hand washing with soap and water before assisting with delivery
Number of subjects: 23662

Group type: EXPERIMENTAL
Intervention: Maternal hand washing with soap and water or antiseptic before handling the baby
Number of subjects: 23662

Group type: EXPERIMENTAL
Intervention: Combined birth attendant and maternal hand washing
Number of subjects: 23662
Study: 15826316

Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil; Cisplatin and 3 million units Interferon alpha-2b for 5 1/2 weeks combined with external beam radiation, followed by continuous 5-FU infusions for two more cycles.
Number of subjects: 110

Group type: COMPARATOR
Intervention: 5-FU with intravenous bolus injections of folinic acid on 5 consecutive days every 28 days for 6 cycles.
Number of subjects: 110
Study: 12186626

Group type: EXPERIMENTAL
Intervention: Quinupristin/dalfopristin
Number of subjects: 0